September 18, 2018

Patagonia is excited to announce that we have been awarded a grant of $1.5MM over three years through FDA's Orphan Products Clinical Trials Grants Program!  This non-dilutive funding will help support our clinical development of PAT-001, a proprietary topical formulation of isotretinoin in development for Congen...

July 6, 2018

Our team just returned from Nashville, TN, where FIRST hosted their biennial, national conference.  It was a fantastic opportunity to engage with a variety of stakeholders within the ichthyosis community, including KOLs, patients, and advocates.  

Our President, Zach Rome, sat on a panel alongside...

June 12, 2018

In a recent blog post from the FDA, Commissioner Scott Gottlieb acknowledges their role to help advance progress in biotechnology.  Their approach will focus on three key areas: "First, advancing and protecting public and animal health by promoting innovation through an efficient and predictable science- and ris...

May 3, 2018

Our team is excited to attend the 20th Biennial FIRST National Conference in Nashville, TN next month.  This will be our second time attending and something we continue to look forward to every couple years.  Not only is it a great opportunity to learn from a variety of stakeholders during the formal presentatio...

April 9, 2018

In March, the President signed the 2018 legislation that increased the budget for nearly all US science agencies, a $1.3 trillion spending deal.  This boosted funding for the National Institutes of Health (NIH) to a historic high of $37 billion, an increase of $3 billion over the 2017 levels. 

Additiona...

February 28, 2018

Each year, on the last day of February, Rare Disease Day is held to raise awareness of rare diseases.  On and around this day hundreds of patient organizations from countries and regions all over the world will hold awareness-raising activities. 

A rare disease, also referred to as an orphan disease, is...

February 13, 2018

Patagonia is excited to announce the completion of our Phase 2a clinical study for PAT-001.  This proof-of-concept study was conducted at 5 sites throughout the United States and investigated the potential of PAT-001 in Congenital Ichthyosis. 

Ichthyosis is a family of genetic skin disorders characteriz...

December 29, 2017

Patagonia is excited to announce that we have completed enrollment in our Phase IIa study for congenital ichthyosis.  Ichthyosis is a family of genetic skin disorders characterized by dry, scaling skin that may be thickened or very thin. It affects people of all ages, races and gender. The disease usually presen...

November 2, 2017

John Maslowski recently published a very interesting article in Pharmaceutical Executive detailing various insights and information related to the developing of treatments for rare diseases.

To read the full article, please click on the following link: http://www.pharmexec.com/developing-drugs-rare-diseases-insig...

October 2, 2017

FDA Commissioner Gottlieb writes a post on the FDA's commitment to the Orphan Drug Act in the FDA Voice blog.  Please click the following link for the full post: 

https://blogs.fda.gov/fdavoice/index.php/2017/09/fda-is-advancing-the-goals-of-the-orphan-drug-act/

Please reload

Recent Posts

July 6, 2018

Please reload

Patagonia Pharmaceuticals, LLC

50 Tice Blvd, Suite A26

Woodcliff Lake, NJ 07677

For more info: info@patagoniarx.com

© 2019 by Patagonia Pharmaceuticals, LLC